Clinical Trial: Isotretinoin, Interferon Alfa-2b, and Paclitaxel in Treating Patients With Stage IV, Recurrent, or Persistent Cervical Cancer

This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) August 2005

Sponsored by: Cancer Institute of New Jersey
Information provided by: National Cancer Institute (NCI) Identifier: NCT00138151


RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Isotretinoin and interferon alfa-2b may help paclitaxel work better by making tumor cells more sensitive to the drug. Giving isotretinoin and interferon alfa-2b together with paclitaxel may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving isotretinoin and interferon alfa-2b together with paclitaxel works in treating patients with stage IV, recurrent, or persistent cervical cancer.

Condition Intervention Phase
recurrent cervical cancer
stage IVB cervical cancer
 Drug: interferon alfa
 Drug: isotretinoin
 Drug: paclitaxel
 Procedure: biological response modifier therapy
 Procedure: chemosensitization/potentiation
 Procedure: chemotherapy
 Procedure: cytokine therapy
 Procedure: drug resistance inhibition
 Procedure: interferon therapy
Phase II

MedlinePlus related topics:  Cervical Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Isotretinoin, Interferon Alfa-2b, and Paclitaxel in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Further Study Details: 


OUTLINE: This is a multicenter study.

Patients receive oral isotretinoin and interferon alfa-2b subcutaneously once daily on days 1-4 and paclitaxel IV over 3 hours on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 27-66 patients will be accrued for this study.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both


  • Histologically and/or cytologically confirmed cervical cancer, meeting 1 of the following criteria:
  • Metastatic disease (stage IVB)
  • Recurrent disease
  • Persistent disease
  • Patients previously treated with chemoradiotherapy as initial therapy must demonstrate disease progression
  • Measurable disease by physical exam or radiographic studies
  • Not amenable to chemoradiotherapy or surgery



  • Over 18

Performance status

  • ECOG 0-2

Life expectancy

  • At least 6 months


  • WBC ≥ 3,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • SGOT and SGPT ≤ 2 times upper limit of normal
  • Bilirubin ≤ 1.5 mg/dL


  • Creatinine ≤ 1.5 mg/dL OR
  • Creatinine clearance ≥ 50 mL/min


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known HIV positivity
  • No active infection
  • No medical condition that would preclude study compliance


Biologic therapy

  • No prior interferon
  • No other concurrent immunotherapy


  • See Disease Characteristics
  • At least 3 months since prior chemoradiotherapy (6 weeks for patients experiencing disease progression after completion of initial chemoradiotherapy)
  • No other concurrent chemotherapy

Endocrine therapy


  • See Disease Characteristics
  • See Chemotherapy
  • Recovered from prior radiotherapy
  • No concurrent radiotherapy


  • Recovered from prior surgery
  • No concurrent surgery for cancer


  • No prior retinoids
  • No other concurrent anticancer therapy
  • No other concurrent experimental agents

Location and Contact Information

Please refer to this study by identifier  NCT00138151

New Jersey
      Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick,  New Jersey,  08901-2681,  United States; Recruiting
Lorna Rodriguez-Rodriguez, MD, PhD  732-235-6777 

      Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown,  New Jersey,  07962,  United States; Recruiting
Steven W. Papish, MD  973-538-5210 

      Saint Peter''''s University Hospital, New Brunswick,  New Jersey,  08901-1780,  United States; Recruiting
Beatriz Lega, MD  732-565-5416 

Study chairs or principal investigators

Lorna Rodriguez-Rodriguez, MD, PhD,  Principal Investigator,  Cancer Institute of New Jersey   

More Information

Clinical trial summary from the National Cancer Institute''''s PDQ® database

Study ID Numbers:  CDR0000433516; CINJ-100101; CINJ-3390; CINJ-NJ1703
Last Updated:  August 29, 2005
Record first received:  August 29, 2005 Identifier:  NCT00138151
Health Authority: United States: Federal Government processed this record on 2005-08-30


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us